MCF Advisors LLC Boosts Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)

MCF Advisors LLC lifted its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 107.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 351 shares of the company’s stock after buying an additional 182 shares during the period. MCF Advisors LLC’s holdings in GeneDx were worth $27,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. CWM LLC purchased a new stake in shares of GeneDx during the 3rd quarter valued at about $89,000. SG Americas Securities LLC purchased a new stake in GeneDx in the third quarter worth approximately $198,000. Point72 DIFC Ltd purchased a new stake in GeneDx in the third quarter worth approximately $220,000. Palumbo Wealth Management LLC bought a new stake in GeneDx in the 3rd quarter worth approximately $287,000. Finally, Franklin Resources Inc. purchased a new stake in GeneDx during the 3rd quarter valued at $301,000. 61.72% of the stock is currently owned by institutional investors.

Insider Buying and Selling at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 51,420 shares of GeneDx stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60. Following the sale, the chief executive officer now directly owns 1,720 shares in the company, valued at approximately $162,505.60. The trade was a 96.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder School Of Medicine At Mo Icahn sold 865,800 shares of the firm’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $75.00, for a total value of $64,935,000.00. Following the transaction, the insider now owns 2,866,833 shares of the company’s stock, valued at approximately $215,012,475. The trade was a 23.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,229,965 shares of company stock valued at $93,006,163 over the last ninety days. 27.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Craig Hallum raised their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. TD Cowen raised their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Wells Fargo & Company upped their price target on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group raised their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $70.67.

GeneDx Trading Up 1.9 %

Shares of NASDAQ:WGS opened at $75.77 on Thursday. GeneDx Holdings Corp. has a 12-month low of $2.85 and a 12-month high of $98.87. The company has a market cap of $2.08 billion, a PE ratio of -24.36 and a beta of 2.02. The stock has a 50 day moving average of $77.59 and a 200 day moving average of $55.94. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. During the same period in the prior year, the company posted ($0.82) earnings per share. The company’s revenue for the quarter was up 44.3% compared to the same quarter last year. As a group, equities research analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.